Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study

Am J Drug Alcohol Abuse. 2017 Jan;43(1):78-86. doi: 10.1080/00952990.2016.1210614. Epub 2016 Aug 11.

Abstract

Background: Treatments for reducing opioid withdrawal are limited and prone to problematic side effects. Laboratory studies, clinical observations, and limited human trial data suggest 5-HT3-receptor antagonists and antihistamines may be effective.

Objectives: This double-blind, crossover, placebo-controlled study employing an acute physical dependence model evaluated whether (i) treatment with a 5-HT3-receptor antagonist (palonosetron) would reduce opioid withdrawal symptoms, and (ii) co-administration of an antihistamine (hydroxyzine) would enhance any treatment effect.

Methods: At timepoint T = 0, healthy (non-opioid dependent, non-substance abuser) male volunteers (N = 10) were pre-treated with either a) placebo, b) palonosetron IV (0.75 mg), or c) palonosetron IV (0.75 mg) and hydroxyzine PO (100 mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10 mg/70kg). At T = 165, 10 mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.

Results: Comparison of average baseline OOWS scores with OOWS scores obtained 15 minutes after naloxone was significant (p = 0.0001). Scores from 15 minutes post-naloxone infusion showed significant differences in OOWS scores between treatment groups: placebo, 3.7 ± 2.4; palonosetron, 1.5 ± 0.97; and palonosetron with hydroxyzine, 0.2 ± 0.1333.

Conclusions: Pretreatment with palonosetron significantly reduced many signs of experimentally-induced opioid withdrawal. Co-administration with hydroxyzine further reduced opioid withdrawal severity. These results suggest that 5-HT3 receptor antagonists, alone or in combination with an antihistamine, may be useful in the treatment of opioid withdrawal.

Trial registration: ClinicalTrials.gov NCT00661674.

Keywords: Palonosetron; antihistamine, 5HT3 antagonist; hydroxyzine; opioid withdrawal.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Cross-Over Studies
  • Double-Blind Method
  • Drug Synergism
  • Healthy Volunteers
  • Humans
  • Hydroxyzine / therapeutic use*
  • Isoquinolines / therapeutic use*
  • Male
  • Morphine / adverse effects
  • Morphine / antagonists & inhibitors
  • Naloxone / pharmacology
  • Palonosetron
  • Quinuclidines / therapeutic use*
  • Substance Withdrawal Syndrome / drug therapy*
  • Young Adult

Substances

  • Isoquinolines
  • Quinuclidines
  • Hydroxyzine
  • Naloxone
  • Palonosetron
  • Morphine

Associated data

  • ClinicalTrials.gov/NCT00661674